IMV Inc. Celebrates Grand Opening of New Facility in Dartmouth, Nova Scotia
September 04, 2018 17:50 ET
|
IMV Inc.
DARTMOUTH, Nova Scotia, Sept. 04, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, celebrated its grand opening today of its new facilities in...
IMV Inc. to Present at the H.C. Wainwright 20th Annual Global Investment Conference
August 23, 2018 07:05 ET
|
IMV Inc.
HALIFAX, Nova Scotia, Aug. 23, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors and...
IMV Inc. Reaches Multiple Milestones in Advanced Ovarian Cancer Clinical Trial
August 09, 2018 07:05 ET
|
IMV Inc.
HALIFAX, Nova Scotia, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Enrollment Completed for Phase 1b CohortsFirst Dosing Occurred in Phase 2 Portion of the Program IMV Inc. (Nasdaq: IMV; TSX: IMV), a...
IMV Inc. Announces Q2 2018 Financial Results
August 08, 2018 07:05 ET
|
IMV Inc.
Initiated Trading of Common Shares on Nasdaq; Finalized Corporate Name ChangePresented New Positive Data at ASCO on the DECIDE1 trial in Ovarian CancerAdvanced Ongoing Clinical Programs with Merck and...
IMV Inc. to Announce Second Quarter 2018 Financial Results and Host Earnings Call on August 8, 2018
July 31, 2018 07:05 ET
|
IMV Inc.
HALIFAX, Nova Scotia, July 31, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (Nasdaq:IMV) (TSX:IMV), a clinical stage immunotherapy company, announced today that it will hold a...
IMV Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference
July 25, 2018 07:05 ET
|
IMV Inc.
HALIFAX, Nova Scotia, July 25, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq:IMV) (TSX:IMV), a clinical stage immuno-oncology corporation, today announced that IMV Chief Executive Officer Frederic Ors...
IMV Inc. Appoints Julia P. Gregory to Board of Directors
June 07, 2018 07:05 ET
|
IMV Inc.
HALIFAX, Nova Scotia, June 07, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (Nasdaq:IMV) (TSX:IMV), a clinical stage immunotherapy company, announced today the addition of Julia P....
IMV Inc. (Formerly Immunovaccine Inc.) Presents New Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ASCO Meeting
June 03, 2018 10:57 ET
|
IMV Inc.
Combination Immunotherapy Continues to Show Tolerable Safety Profile and Promising Activity With Second Dosing Cohort Showing 6 of the First 8 Evaluable Participants Exhibiting Stable Disease at First...
Nasdaq Approves Listing of IMV Inc. Common Shares
May 31, 2018 07:05 ET
|
IMV Inc.
HALIFAX, Nova Scotia, May 31, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (TSX:IMV) (OTCQX:IMMVD), a clinical stage immunotherapy company, today announced that its common shares...
IMV Leadership to Participate in Upcoming Investor and Business Development Conferences
May 30, 2018 16:35 ET
|
IMV Inc.
HALIFAX, Nova Scotia, May 30, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (TSX:IMV) (OTCQX:IMMVD), a clinical stage immuno-oncology company, today announced details on upcoming industry presentations that the...